Different inhibitory potencies of oseltamivir carboxylate, zanamivir, and several tannins on bacterial and viral neuraminidases as assessed in a cell-free fluorescence-based enzyme inhibition assay by Quosdorf, S. et al.
molecules
Article
Different Inhibitory Potencies of Oseltamivir
Carboxylate, Zanamivir, and Several Tannins on
Bacterial and Viral Neuraminidases as Assessed in a
Cell-Free Fluorescence-Based Enzyme
Inhibition Assay
Stefanie Quosdorf 1, Anja Schuetz 2,† and Herbert Kolodziej 1,*,†
1 Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany;
stquosdorf@gmail.com
2 Max-Delbrück-Centrum for Molecular Medicine, Helmholtz Protein Sample Production Facility,
Robert-Rössle-Str. 10, 13125 Berlin, Germany; anja.schuetz@mdc-berlin.de
* Correspondence: kolpharm@zedat.fu-berlin.de; Tel.: +49-30-838-53731
† These authors share last authorship.
Received: 23 October 2017; Accepted: 15 November 2017; Published: 17 November 2017
Abstract: Neuraminidase is a key enzyme in the life cycle of influenza viruses and is present
in some bacterial pathogens. We here assess the inhibitory potency of plant tannins versus
clinically used inhibitors on both a viral and a bacterial model neuraminidase by applying the
2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA)-based activity assay. A range
of flavan-3-ols, ellagitannins and chemically defined proanthocyanidin fractions was evaluated in
comparison to oseltamivir carboxylate and zanamivir for their inhibitory activities against viral
influenza A (H1N1) and bacterial Vibrio cholerae neuraminidase (VCNA). Compared to the positive
controls, all tested polyphenols displayed a weak inhibition of the viral enzyme but similar or
even higher potency on the bacterial neuraminidase. Structure–activity relationship analyses
revealed the presence of galloyl groups and the hydroxylation pattern of the flavan skeleton to
be crucial for inhibitory activity. The combination of zanamivir and EPs® 7630 (root extract of
Pelargonium sidoides) showed synergistic inhibitory effects on the bacterial neuraminidase. Co-crystal
structures of VCNA with oseltamivir carboxylate and zanamivir provided insight into bacterial
versus viral enzyme-inhibitor interactions. The current data clearly indicate that inhibitor potency
strongly depends on the biological origin of the enzyme and that results are not readily transferable.
The therapeutic relevance of our findings is briefly discussed.
Keywords: neuraminidase; inhibition; tannins; oseltamivir carboxylate; zanamivir; crystal structure;
molecular interactions
1. Introduction
Influenza is an acute viral infection of the respiratory tract, afflicting millions of individuals each
year. Due to the imminent threat of epidemics and pandemics in human population and the alarming
emergence of drug-resistant influenza virus strains, there is an urgent need for new and effective
anti-influenza drugs.
The influenza virus employs two key enzymes located on the surface, hemagglutinin (HA) and
neuraminidase (NA), to initiate viral fusion and subsequent budding of progeny virions from the
infected cell [1]. In the virus infection life cycle, HA binds to terminally linked sialic acid receptors
on target cells, thus facilitating entry of the virus into the host cell. NA plays a key role not only
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in the release of virions from infected host cells by cleaving terminal sialic acid residues but also in
preventing self-aggregation of the released influenza viruses, thereby allowing continuous and efficient
viral replication.
Annual vaccination has been the main global strategy for preventing influenza infections,
but frequent virus antigenic drifts present a permanent challenge in the development of effective
vaccines. Antiviral drugs offer an alternative therapeutic option. Currently, there are two classes
of anti-influenza drugs available, matrix-2 (M2) protein ion channel blockers and neuraminidase
inhibitors (NAIs). The therapeutic efficacy of M2 ion channel blockers such as amantadine and
rimantadine is limited to influenza A viruses. These therapeutics are also associated with the rapid
emergence of drug resistance and have the disadvantage of side effects. At present, the approved NAIs
oseltamivir, zanamivir, peramivir, and laninamivir are first choice antiviral drugs for the treatment of
influenza A and B virus infections. Until the season 2007/2008, NAI-resistance to the first introduced
NA-targeting drugs has been reported only sporadically [2]. Over the years, the emergence of
oseltamivir-resistant strains is a cause for concern. Nevertheless, NAIs are currently considered to be
the most promising drugs for combating influenza A and B. Despite their considerable therapeutic
potential, the number of approved competitive inhibitors of the influenza NA is rather limited to date.
Taking into account the serious problem of resistance development from antigenic shifts or drifts,
there is a persistent demand to develop new NAIs.
A successful modus operandi for finding promising antiviral agents involves the exploration of
plants and their chemical constituents. The plant kingdom has been recognized as an inestimably
rich source of metabolites for target-oriented drug discovery. In particular, various plant polyphenols
that have a broad spectrum of other biological activities have been identified to possess viral NA
inhibitory activities [3–5]. Although isolated pure products have been preferentially elucidated for this
bioactivity, some plant extracts, in particular traditional Chinese medicines have been subjected to
anti-influenza activity studies [6–9].
NAs are also present in other biological systems [10], for example bacteria, and these non-influenza
NAs are critical virulence factors in many pathogenic organisms including Streptococcus pneumoniae,
Pseudomonas aeruginosa, and Vibrio cholerae [5,11,12]. Bacterial sialidases have been suggested to
promote microbial survival and to contribute to microbe–host interactions [13]. Their function in
pathogenesis remains to be clarified. However, bacterial NA activity has been shown to contribute to
respiratory tract infections in a mouse model [14]. Taking into account the demonstrated synergism
between influenza virus and bacterial pathogens in pulmonary infectious conditions resulting from
the exposure of pneumococcal receptors [15], bacterial NAs may be an appealing target to prevent
microbial colonization.
Established functional assays to assess NA inhibitory activities are based on either fluorescence or
chemiluminescence and are reported to be compared to culture-based assays, more predictive in terms
of their in vivo susceptibility [3]. The in vitro NA inhibition assays work with both viral and bacterial
NAs, because the enzymes recognize the applied substrates independent of their biological origin [16].
The use of commercially available bacterial or viral NA-based test systems may be beneficial for a
given pathogenic condition. In addition, bacterial NA-based setups are less expensive and are used
for antiviral activity studies in laboratories. To date, however, comparative studies on the effect of
tannins on bacterial and viral NAs are lacking. These comparisons could allow for the evaluation
of the therapeutic significance of bacterial enzyme inhibition data in the identification of anti-viral
substances [3].
To fill this gap, we here disclose results for the inhibition of both a viral and a bacterial model
NA by various tannins. In addition to a range of flavan-3-ols and ellagitannins, highly purified and
chemically defined proanthocyanidin fractions of different composition were included to gain insight
into structure–activity relationships for this group of polyphenols. To provide a rationale for differential
inhibition of bacterial and viral NAs, we additionally performed X-ray crystallographic analyses of
NAs in complex with the synthetic reference compounds oseltamivir carboxylate and zanamivir.
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2. Results
Preliminary experiments in our research group have indicated differential inhibition of bacterial
and viral NAs by some polyphenolic substances [17] and have prompted the present more detailed
study. We here explore the structure–activity relationship of a range of polyphenolic NAIs using the
well-established 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA)-based activity
assay [18]. The assay is based on the NA-catalyzed hydrolysis of the substrate MUNANA and
quantification of the released fluorochrome 4-methylumbelliferone (Figure 1). The established
NAIs oseltamivir carboxylate (active form of oseltamivir) and zanamivir were included as
reference compounds.
Figure 1. Neuraminidase-catalyzed hydrolysis of 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic
acid (MUNANA).
2.1. Inhibition of Viral Influenza a Neuraminidase and Bacterial Vibrio Cholerae Neuraminidase by the
Reference Compounds
To validate our assay conditions, we first assessed the inhibitory potency of the reference NAIs
oseltamivir carboxylate and zanamivir (Figure 2) against both the viral influenza A/California/04/2009
(H1N1) neuraminidase (H1N1-NA) and the bacterial Vibrio cholerae neuraminidase (VCNA). With IC50
values (the inhibitor concentration that is required for 50% inhibition) of around 10 nM, oseltamivir
carboxylate and zanamivir are very active against the viral H1N1-NA. The bacterial VCNA, on the
other hand, is only moderately inhibited by the reference compounds, displaying IC50 values of 144 µM
for oseltamivir carboxylate and 52 µM for zanamivir. These IC50 values are comparable to other NA
inhibition data [19,20], although modified assay conditions were used.
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Figure 2. Chemical structures of tested flavan-3-ols, proanthocyanidins, oseltamivir carboxylate,
and zanamivir.
2.2. Inhibition of Viral H1N1-NA and Bacterial VCNA by Flavan-3-ols
The inhibitory potencies of a series of flavan-3-ols are shown in Table 1, revealing markedly
different inhibitory activities towards the bacterial and viral NAs. All tested flavan-3-ols (Figure 2)
display only moderate to very weak inhibitory activities against the viral H1N1-NA when
compared to the synthetic reference inhibitors. The IC50 values range from 0.3 to 0.9 mM,
and gallocatechin-3-O-gallate is the most active compound within this series. This finding is consistent
with modest inhibitory activities (>100 µM) reported for (epi)catechin [3].
Table 1. IC50 values for the inhibition of viral influenza A (H1N1) neuraminidase (H1N1-NA) and
bacterial Vibrio cholerae neuraminidase (VCNA) by flavan-3-ols.
Test Substance IC50 (Viral) µg/mL µM IC50 (Bacterial) µg/mL µM
Positive control
oseltamivir carboxylate 2.9 ± 0.2 (1) 0.01 ± 0.001 41 ± 1 144 ± 1
zanamivir 3.7 ± 0.4 (1) 0.01 ± 0.001 17 ± 1 52 ± 2
Flavan-3-ols
catechin 312 ± 21 1076 ± 75 595 ± 25 2050 ± 87
gallocatechin 547 ± 23 1787 ± 74 603 ± 61 1969 ± 199
catechin-3-O-gallate 862 ± 2 1949 ± 4 24 ± 2 55 ± 4
gallocatechin-3-O-gallate 181 ± 3 396 ± 7 11 ± 1 25 ± 2
epicatechin 305 ± 19 1053 ± 64 670 ± 29 2186 ± 99
epigallocatechin 532 ± 41 1739 ± 135 598 ± 57 1955 ± 185
epicatechin-3-O-gallate 845 ± 24 1910 ± 55 93 ± 8 211 ± 19
epigallocatechin-3-O-gallate 717 ± 63 1565 ± 137 29 ± 1 64 ± 3
IC50 values are expressed as mean± standard deviation (SD) (n = 3–6 independent experiments); (1) data are in ng/mL.
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In contrast, these compounds are effective inhibitors of the bacterial VCNA. The flavan-3-ols
gallocatechin-3-O-gallate (IC50 = 25 µM), catechin-3-O-gallate (IC50 = 55 µM), and epigallocatechin-3-
O-gallate (IC50 = 64 µM) have comparable or greater potency compared to the reference compounds
(Table 1). All tested non-galloylated flavan-3-ols, on the other hand, show comparatively weak
inhibitory activities, indicating that a 3-O-galloyl group is crucial for pronounced inhibition of VCNA
by polyphenols. The enhanced inhibitory activity of the 2,3-trans galloylated flavan-3-ols compared
with their 2,3-cis analogues suggests that the relative 2,3-configuration is, to some extent, an additional
structural feature contributing to the inhibition of the bacterial NA.
2.3. Inhibition of Viral H1N1-NA and Bacterial VCNA by Ellagitannins
We next evaluated the inhibitory potency of a series of ellagitannins (Figure 3), including members
of dehydroellagitannins and C-glycosidic ellagitannins. All ellagitannins inhibit bacterial VCNA with
an IC50 value of 15–236 µM. The most potent compounds, which were even more effective than
zanamivir, are paeonianin C (IC50 = 15 µM) and terchebin (IC50 = 31 µM). In tests with the viral
H1N1-NA, the inhibition is also in the µM range, but terchebin showed a 3.5-fold higher inhibitory
potency compared to paeonianin C (Table 2). Overall, the ellagitannins are less effective against the
viral compared to the bacterial NA. It is also worth mentioning that the only moderately effective
VCNA ellagitannin inhibitors are still as potent as the reference compound oseltamivir carboxylate.
A structural element characteristic of dehydroellagitannins is the presence of at least one
dehydrohexahydroxydiphenoyl (DHHDP) unit in addition to a varying number of galloyl groups
on the glucose core. Structure–activity relationship analyses indicate that the inhibitory activity of
the tested compounds depends in part on the degree of galloylation. As shown in Table 2, inhibition
decreased in the order of terchebin > geraniin > carpinusin > granatin A (IC50 values of 31, 135, 138
and 158 µM), corresponding to three, one, and no galloyl groups. Further examination of the structures
revealed that the presence of additional 1′,6′- or 3′,6′-hexahydroxydiphenoyl (HHDP) residue (Figure 3)
results in significantly weaker inhibitory activities, possibly due to steric effects.
Figure 3. Cont.
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Figure 3. Chemical structures of ellagitannins. (A) Dehydroellagitannins and (B) C-glycosidic members
(DHHDP = dehydrohexahydroxydiphenoyl; HHDP = hexahydroxydiphenoyl).
Table 2. IC50 values for the inhibition of viral H1N1-NA and bacterial VCNA by ellagitannins.
Test Substance IC50 (Viral) µg/mL µM IC50 (Bacterial) µg/mL µM
Positive control
oseltamivir acid 2.9 ± 0.2 (1) 0.01 ± 0.001 41 ± 1 144 ± 1
zanamivir 3.7 ± 0.4 (1) 0.01 ± 0.001 17 ± 1 52 ± 2
Ellagitannins
dehydroellagitannin members
geraniin - - 128 ± 2 135 ± 2
granatin A - - 124 ± 2 158 ± 4
carpinusin - - 131 ± 5 138 ± 5
terchebin 97 ± 2 101 ± 3 29 ± 2 31 ± 2
C-glycosidic members
casuariin - - 185 ± 4 236 ± 5
vescalagin - - 125 ± 11 73 ± 11
paeonianin C 587 ± 24 344 ± 14 25 ± 2 15 ± 1
IC50 values are expressed as mean ± SD (n = 3–6 independent experiments); (1) data are in ng/mL.
Although the number of tested C-glycosidic ellagitannins was limited, some structural features
determining inhibitory potency were evident. Paeonianin C, possessing a 1C-penta-O-galloyl
glucose moiety, was significantly more potent (IC50 = 15 µM) than vescalagin (IC50 = 73 µM),
having a 4,6-HHDP and a 2,3,5-flavogalloyl unit, and casuariin (IC50 = 236 µM), which lacks the
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5-O-galloyl residue as part of the flavogalloyl group. The inhibition correlates with the number
of pyrogallol elements. More information is needed to decide between galloyl-derived structural
variants. However, it appears that the conformation of these molecules with bulky substituents
plays a significant role and more C-glycosidic ellagitannins need to be tested to fully understand the
structure–activity relationships.
2.4. Inhibition of Viral H1N1-NA and Bacterial VCNA by Plant-Derived Fractions
Proanthocyanidins are oligomeric flavan-3-ols and represent another group of plant tannins.
Extensive structural variations and challenges in the isolation and purification of chemically defined
proanthocyanidins prompted the evaluation of well-characterized plant fractions. Table 3 lists the
main component of the composite fractions and the resulting IC50 values for both viral H1N1-NA and
bacterial VCNA inhibition. Most of the tannin fractions inhibit the bacterial VCNA significantly better
than the reference compounds. The inhibition of viral H1N1 is reduced by a factor of 6–10 compared
to the clinically used inhibitors, leaving potential for further optimization.
Table 3. IC50 values for the inhibition of viral H1N1-NA and bacterial VCNA by tannin fractions.
Tested Substance Constituent Flavanyl Units IC50 (Viral) µg/mL IC50 (Bacterial) µg/mL
Positive control
oseltamivir acid 2.9 ± 0.2 (1) 41 ± 1
zanamivir 3.7 ± 0.4 (1) 17 ± 1
Tannin fractions
Diospyros kaki galloylated flavan-3-ols 20 ± 1 0.5 ± 0.04
EPs® 7630 (2) (epi)gallocatechin/(epi)catechin 61 ± 2 1.7 ± 0.1
Nelia meyeri epicatechin 29 ± 1 3.2 ± 0.1
Salix ssp. catechin 32 ± 3 4.4 ± 0.2
Potentilla erecta epicatechin/catechin - 9.2 ± 1
Betula spp. epicatechin/catechin - 13 ± 1
Rhus leptodictya fisetinidol - 25 ± 1
IC50 values are expressed as mean ± SD (n = 3–6 independent experiments); (1) data are in ng/mL; (2) proportion of
polyphenols ca. 40%. EPs® 7630 (root extract of Pelargonium sidoides).
For both NAs, the Diospyros kaki sample is the most active fraction, suggesting that pyrogallol
B-ring elements (prodelphinidin units) and 3-O-galloylation are preferred structural determinants
for NA inhibition. In line with this, weaker inhibitory activity is found for the prodelphinidin-rich
but mainly ungalloylated extract of Pelargonium sidoides EPs® 7630 extract. The trend continues
for the Nelia meyeri and Salix spp. fractions, which comprise either homogeneous 2,3-cis or
2,3-trans proanthocyanidins composed of non-galloylated dimers to hexamers in similar proportions.
Interestingly, fractions with mixed 2,3-trans and 2,3-cis constituent flavanyl units obtained from
Potentilla erecta and Betula spp. are less potent than preparations dominated by compounds with
the homogeneously linked building blocks. Increasing proportions of 2,3-cis entities as in the Betula
fraction apparently reduces the inhibitory activity (Table 3). More studies with fractions of defined
2,3-cis/2,3-trans ratios and a focus on the impact of the molecular weight are fruitful avenues for
future research.
The data additionally show the relatively poor activity of 5-deoxy analogues, such as the
compounds in the Rhus leptodictya fraction. The profisetinidins with characteristic resorcinol
A-rings show the weakest inhibition within the series of tested proanthocyanidin fractions.
The hydroxylation pattern on the two aromatic rings of the flavan skeleton thus proves to be an
important structural feature.
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2.5. Combined Effect of Zanamivir and EPs® 7630 on VCNA Activity
Possible beneficial effects of combination therapy include synergistic activity, reduced dosage
with decrease of side effects, and delay or prevention of development of drug resistance. Indeed,
previous reports have stated advantages of synthetic NAI combinations over single-drug influenza
treatment [21–24]. Additionally, drug–herb combinations such as the Manuka honey constituent
methylglyoxal along with oseltamivir [25] as well as also some entirely herbal-based combinations [26]
proved to be effective anti-influenza NAIs.
Recent work indicates that bacterial NAs play a role in the pathogenesis of respiratory tract
infections [14]. However, little information is available on natural products inhibiting bacterial NA
activity. We thus examined the hitherto less studied drug–herb combination approach and determined
the combined effect of zanamivir and EPs® 7630 on bacterial VCNA using the median-plot effect
analysis [27,28]. Selection of EPs® 7630 was based on its VCNA-inhibition potential demonstrated in
this study and its approval for the treatment of acute bronchitis [29]. The clinically used drug zanamivir
was chosen because it is more effective against VCNA than oseltamivir carboxylate against VCNA.
The enzyme was treated with zanamivir and EPs® 7630 either individually over a range of
concentrations or in combination at different weight ratios (1:10, 1:5, 1:1, 5:1, or 10:1) (Table 4).
The median–effect concentration (Dm, a parameter analogous to the IC50 value indicating potency),
the slope of the concentration–effect relationship (m, the dynamic order or the shape of dose–effect
curve), and the linear regression correlation coefficient (r, a measure of data quality) were determined
from the median–effect plots. The parameter r of the median–effect plots exceeds 0.95 (data not shown),
showing the conformity of the data to the median–effect principle. The calculated Dm values indicate
an enhanced VCNA inhibition with increasing amounts of EPs® 7630 (ratio of 1:5 and 1:10, Dm = 1.4)
as compared to zanamivir alone (Dm = 17).
Table 4. Concentration–effect relationship parameters and mean combination index (CI) values of
zanamivir and EPs® 7630 alone and in combinations for the inhibition of the bacterial VCNA.
Compound Concentration–Effect Parameters CI Values at CIwt Combined Effect
Dm m IC50 IC75 IC90 IC95
zanamivir 17.0 ± 1 0.9 - - - - -
EPs® 7630 1.7 ± 0.1 1.4 - - - - -
Ratio of Zanamivir and EPs® 7630
5:1 7.8 ± 0.6 1.1 1.1 0.7 0.5 0.4 0.5 synergistic
10:1 9.1 ± 0.4 1.7 0.9 0.7 0.6 0.5 0.6 synergistic
1:1 7.8 ± 0.6 1.7 2.3 1.8 1.5 1.3 1.6 antagonistic
1:5 1.4 ± 0.1 1.2 0.7 0.8 1.0 1.1 1.0 additive
1:10 1.4 ± 0.2 1.0 0.7 0.8 0.8 0.9 0.8 moderate synergistic
The parameters Dm (antilog of the x-intercept) and m (slope) are derived from the median effect plot and are used
to calculate the CI values (n = 3–4 experiments). IC50, IC75, IC90 and IC95 are the concentrations (µg/mL) that
achieve 50%, 75%, 90% and 95% inhibition of VCNA. The weighted CI (CIwt) is calculated on the basis of these
representative CI values at effect levels fa > 0.5.
We calculated the combination index (CI) values that offer a quantitative definition for an additive
effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations [27,28]. CI values
were determined at IC50, IC75, IC90, and IC95, indicating the concentrations required to achieve 50%,
75%, 90% or 95% inhibition of VCNA activity. It should be noted that only CIs of higher effect
levels (fraction affected values, fa > 0.5) are considered relevant for therapeutic applications [30].
The fa-CI plots for various zanamivir/EPs® 7630 combinations are shown in Figure 4. The CI values are
concentration-dependent and are generally higher with lower sample concentrations. The tendency of
combined effects moving from antagonism towards additivity and synergism as effect levels increase,
appears to be a common phenomenon. Indeed, antagonism is restricted to the region of lower fa values
in our study. For higher effect levels, CI values move to synergism except for the 1:1 combination,
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exhibiting continuously antagonistic effects (Figure 4). The combined effect (CIwt) was calculated on
the basis of selected average CI values including IC50, IC75, IC90 and IC95 at four representative effect
levels (fa > 0.5). The most effective combinations include drug–herb ratios of 10:1, 5:1, and, surprisingly,
1:10, with CIs ranging between 0.5 and 0.8, indicative of synergism. For the zanamivir/EPs® 7630
combination with a ratio of 1:5, the CI revealed additivity.
Figure 4. Fraction affected (fa)–CI-plot for VCNA activity measurements by zanamivir/EPs®
7630-combinations. The vertical bars indicate 95% confidence intervals (n = 3–4 independent experiments).
Differences in the slopes of the median effect plots for EPs® 7630 (m > 1, sigmoidal) and zanamivir
(m < 1, flat sigmoidal) alone and for the tested combinations (all m > 1) indicate possible different
binding sites for each compound. Therefore, the data were reanalyzed with an assumption of
non-exclusivity for the calculations of CI values of the tested combinations (Table S1). However,
the overall combined effects (CIwt) are very similar for all the tested combinations, whether the
calculation was based on exclusivity or non-exclusivity. Further analyses of the complex EPs® 7630
extract composition [29,31] might be beneficial, but are beyond the scope of this work.
2.6. Molecular Basis of NA-Inhibitor Interactions as Assessed by Crystallographic Analyses
The in vitro studies presented here unambiguously show the different inhibitory potency of
tannins against bacterial and viral NAs. To better understand the differential NA–tannin interactions
at the molecular level and to assess the specificity of tannin binding, we aimed at solving the crystal
structures of various NA–flavan-3-ol complexes. These attempts, however, remained unsuccessful.
Instead, we solved the crystal structures of bacterial VCNA in complex with the reference compounds
oseltamivir carboxylate and zanamivir at 1.87 and 1.75 Å resolution (Figure S1), allowing a comparative
analysis of bacterial versus viral enzyme-inhibitor interactions for these synthetic substances.
Data collection and refinement statistics are reported in Table 5.
The uncomplexed crystal structures of influenza A H1N1-NA and bacterial VCNA have been
previously published. The enzymes have different overall structural topologies. The viral enzyme
is a mushroom-like shaped homotetramer, while the bacterial NA is a monomer with two flanking
lectin-like domains [32–34]. Both enzymes share the canonical six-blade β-propeller fold of the catalytic
NA domain, despite exhibiting a relatively low amino acid sequence identity of only 12% as revealed
by structure-based sequence alignment (Figure S2). Co-crystal structures of H1N1-NA in complex with
zanamivir and oseltamivir carboxylate are publicly available (Protein Data Bank (PDB) ID codes 3TI5
and 3TI6) [19], and were used for the following detailed comparison of protein–ligand interactions
with the herein determined new bacterial VCNA complex structures.
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Table 5. Data collection and refinement statistics for determined VCNA-inhibitor complex structures.
Oseltamivir Carboxylate Zanamivir
Data Collection
Space group P212121 C121
Cell dimension
a, b, c (Å) 71.76, 77.86, 163.48 190.55, 50.34, 86.09
α, β, γ (˚) 90, 90, 90 90, 107.24, 90
Resolution (Å) 44.33–1.87 (1.94–1.87) * 46.00–1.75 (1.81–1.75)
Rmerge (%) 10.1 (49.6) 4.4 (47.8)
<I/σ(I)> 10.2 (2.4) 14.7 (1.8)
Completeness (%) 99.2 (97.9) 97.8 (96.8)
Multiplicity 3.7 (3.5) 2.3 (2.2)
Refinement
Resolution (Å) 44.33–1.87 46.00–1.75
No. reflections 282260 176727
Rwork/Rfree (%) 16.31/20.44 16.69/20.29
No. atoms 6632 6569
Protein 5834 5852
Ligand/ion 42 57
Water 756 660
Average B-factor (Å2)
Overall 24.3 32.0
Protein 23.4 31.3
Ligand/ion 22.7 36.0
Water 31.9 38.0
R.m.s. deviations
Bond lengths (Å) 0.010 0.007
Bond angles (˚) 1.18 1.05
One single-crystal was used to collect a complete dataset for every structure. * Highest resolution shell is shown
in parenthesis.
A common feature of viral and bacterial inhibitor binding is the electrostatic and hydrogen
bonding interaction of the carboxylic acid group of oseltamivir carboxylate or zanamivir to a cluster
of three positionally conserved arginine residues (Arg224, Arg635, and Arg712 in VCNA; Arg118,
Arg292, and Arg371 in H1N1-NA) (Figure 5, Tables S2 and S3). Notably, Arg224 of VCNA belongs
to the bacterially conserved RIP/RLP motif and Arg118 of H1N1-NA belongs to the corresponding
REP motif of viral NAs [35]. A second common structural feature is the electrostatic and hydrogen
bonding interaction of the 5-amino group of oseltamivir carboxylate or the 4-guanidino moiety of
zanamivir with an electronegative binding pocket within the active site (Glu243, Arg 245, Asp250 and
Asp292 in VCNA; Glu119, Asp151, and Glu227 in H1N1-NA) (Figure 5, Tables S2 and S3). Notable
differences between viral and bacterial inhibitor complexes are observed in the surrounding region of
the acetamido moiety of oseltamivir carboxylate and zanamivir. In viral H1N1-NA, the side chain of
Arg152 is hydrogen bonded to the acetamido moiety of the inhibitors, an interaction that is missing
in the bacterial complexes (Figure 5). Moreover, the acetamido binding cavity in bacterial VCNA is
sterically constrained by the short amino acid stretch of Gln317 and Asn318 that extends into the active
site. Another steric restriction in the bacterial VCNA active site is seen in the microenvironment around
the 5-amino group of oseltamivir carboxylate and the 4-guanidino moiety of zanamivir. Glu243 and
Arg245 extend further into the active site compared to Leu134 and Arg156 of the influenza enzyme,
thereby reducing the available space in that subpocket. Thus, oseltamivir carboxylate and zanamivir
fit much better into the active site of influenza H1N1-NA than that of bacterial VCNA, consistent
with their relative inhibitory potencies (Table 1). Taken together, the structural differences between
H1N1-NA and VCNA inhibitor complexes contribute to the observed differential inhibition of viral
and bacterial NA by oseltamivir carboxylate and zanamivir.
Molecules 2017, 22, 1989 11 of 18
Figure 5. Binding modes of zanamivir (left, green stick model) and oseltamivir carboxylate (right, green
stick model) in the active site of (A) VCNA, determined in this study (Protein Data Bank (PDB) codes
6EKU and 6EKS); and (B) H1N1-NA (PDB codes 3TI5 and 3TI6) [19]. Hydrogen bonds are depicted
with dashed blue lines and hydrophobic interactions are shown as red arcs. The figures were prepared
with LIGPLOT+ [36].
To rationalize the observed increased inhibitory activity of zanamivir over oseltamivir carboxylate
for bacterial VCNA (IC50 of 52 µM versus 144 µM, Table 1), we compared the inhibitor interactions
in the determined VCNA complex structures. The interaction network differs most in those regions
where the chemical structure of the inhibitors is different. The 4-guanidino group of zanamivir,
for example, forms electrostatic and hydrogen bonding interactions with Glu243, Arg245, and Asp292,
whereas the 5-amino group of oseltamivir carboxylate interacts with Arg250 only (Figure 5, Table S3).
The hydrophilic 6-(1′,2′,3′)-trihydroxypropyl group of zanamivir hydrogen bonds with Asn318 and
Asp637, the corresponding 3-(1′-ethylpropoxy) group of oseltamivir carboxylate, however, interacts
only hydrophobically. Furthermore, the oxygen within the 5,6-dihydro-4H-pyran ring of zanamivir
forms a hydrogen bond with the side chain of Tyr740, while the cyclohex-1-ene entity of oseltamivir
carboxylate interacts exclusively hydrophobically (Figure 5, Table S3). Summarizing, the elevated
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number of hydrogen bonds in the zanamivir complex likely explains the increased potency of zanamivir
over oseltamivir carboxylate for bacterial VCNA inhibition.
3. Discussion
The current data clearly indicate a differential inhibition of the viral H1N1-NA and bacterial
VCNA by the various tested tannins and the reference compounds. While oseltamivir carboxylate
and zanamivir showed pronounced inhibition of the viral H1N1-NA, the polyphenolic substances
were more effective against bacterial VCNA. Thus, IC50 values obtained from a fluorometric activity
assay using neuraminidases of different biological origin are not readily comparable and it is
therefore advisable to select viral NAs when screening compounds for their anti-influenza potencies,
and bacterial NAs when the testing is aimed at targeting bacterial pathogens.
Previous structure–activity relationship analyses of various groups of flavonoids revealed
that the presence of the 4-keto function and the C2–C3 double bond are relevant structural
elements for potent viral NA inhibition [3,37]. These chemical features are “missing” in flavan-type
molecules such as the flavan-3-ols tested in this study, consistent with their weak viral inhibitory
activity. In contrast, oligomeric flavan-3-ols (proanthocyanidins) show more promise as antiviral
candidates. A computational virtual screening recorded proanthocyanidins within the top ranked
plant metabolites selected from ligand databases, but detailed chemical information is lacking [38].
We demonstrate that pure fractions of proanthocyanidins are only 6–10 times less potent compared
with the viral-specific reference NA inhibitors. Given the bioactive potential of proanthocyanidins,
compositional extract optimization and structural modifications may improve their ability to inhibit
viral NAs. Proanthocyanidins may furthermore be sufficiently active against influenza by different
modes of action. Targets other than NAs could well provide more potent antiviral effects as exemplarily
reported for EPs® 7630 [39].
Next to possible antiviral effects, tannins may also be beneficial for treating bacterial infections.
Importantly, NAs of many bacterial, respiratory pathogens play a key role in early stages of pulmonary
infection by forming biofilms that contribute to initial colonization of the respiratory tract [14]. Bacterial
NAs may additionally be involved in the pathogenesis of enteric bacterial infections [40]. Modulation
of bacterial NAs by, for example, secondary plant products thus presents an appealing approach to
prevent bacterial infection of the respiratory tract and to maintain gut homeostasis. We analyzed the
inhibitory potential of a series of flavan-3-ols and chemically defined proanthocyanidin fractions on
the bacterial NA from Vibrio cholerae. Compared to the reference NAIs, the proanthocyanidin samples
are significantly more potent. We demonstrate that the hydroxylation pattern of the flavan skeleton of
the inhibitors and the presence of a 3-O-galloyl group is a key structural feature for effective VCNA
inhibition. Moreover, inhibitor potency is correlated with the number of molecular interactions within
the active site as shown by our crystal structure analysis of VCNA complexes with zanamivir and
oseltamivir carboxylate. Within the series of ellagitannins, paeonianin C and terchebin show superior
VCNA inhibitory activities compared to zanamivir and oseltamivir carboxylate, a finding that deserves
further attention. Overall, tannins exhibit remarkable VCNA inhibitory potencies, a stimulus for
similar studies on other bacterial NAs.
The impact of oseltamivir carboxylate and zanamivir on the activity of other bacterial NAs has
been reported in previous publications [41–43]. The Streptococcus pneumoniae NA NanA, for example,
has a Ki value of 1.77 µM for oseltamivir carboxylate and 0.72 mM for zanamivir [41]. Also the
Ruminococcus gnavus NA is more effectively inhibited by oseltamivir carboxylate than by zanamivir
(IC50 of 30 µM versus 11.89 mM) [42]. In contrast, we observed an increased inhibitory activity of
zanamivir over oseltamivir carboxylate for bacterial VCNA (IC50 of 52 µM versus 144 µM, Table 1),
consistent with recent findings [44]. This highlights the difficulties in translating structure-based drug
developments even between bacterial NAs of different origin, though NAs share a similar fold in their
active sites [43].
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Another important finding of our study is that the drug–herb combination zanamivir and EPs®
7630 is a more potent inhibitor of bacterial VCNA than either compound alone, suggesting promising
benefits of similar combinatory therapies. Clinical studies are needed to approve the therapeutic
potential. The fact that herbal medicines are increasingly used as an adjuvant treatment of both
bacterial and viral infections makes this field a promising but challenging research in the future.
Finally, absorption, distribution in tissues, and metabolism are important efficacy-influencing
parameters. The intestine and its microbiota play a crucial role in this process. Further research is
needed to clarify the impact of microbial degradation of tannins and their metabolites on health effects.
4. Materials and Methods
4.1. Chemicals
4-Methylumbelliferone, 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA),
and 2-(N-morpholino) ethanesulfonic acid (MES) were purchased from Sigma Aldrich
(Taufkirchen Germany). Sources of NAIs: Oseltamivir carboxylate (5-N-acetyl-3-(1-ethylpropyl-
1-cyclohexene-1-carboxylic acid), the active form of oseltamivir, was kindly supplied by Hoffmann La
Roche (Basel, Switzerland) and zanamivir (2,4-dideoxy-2,3-didehydro-4-guanidino- N-acetylneuraminic
acid) by GlaxoSmithKline (Brentford, Middlesex, UK). All flavan-3-ols (purity > 95%) were commercially
obtained (catechin, Roth, Germany; gallocatechin and catechin-3-O-gallate, Sigma Aldrich, Taufkirchen,
Germany; gallocatechin-3-O-gallate and epicatechin, Fluka, Switzerland; epigallocatechin, Alfa Aesar,
Germany; epicatechin-3-O-gallate, AppliChem, Darmstadt, Germany; epigallocatechin-3-O-gallate,
Tocris Bioscience, Bristol, UK), while the ellagitannins are generous gifts from Prof. T. Yoshida,
Okayama University, Japan. The highly purified proanthocyanidin fractions obtained from Nelia meyeri,
Salix spp., Betula spp., Potentilla erecta, Rhus leptodictya, and Diospyros kaki were available in our research
group. The preparation and characterization of the oligomeric proanthocyanidin mixtures are described
elsewhere [45–50]. The root extract of Pelargonium sidoides (EPs® 7630, an aqueous-ethanolic extract),
was obtained from Dr. Willmar Schwabe Pharmaceuticals (Karlsruhe, Germany).
4.2. NA Inhibition Assay
To assess NA activity, a fluorometric NA inhibition assay using MUNANA as a substrate and
commercially available Vibrio cholerae NA was performed [18]. VCNA (Hoffmann La Roche, Basel,
Switzerland) (1 U stock) was diluted 1:10 in MES-buffer (34.8 µM MES-NaOH pH 6.5, 4 mM CaCl2)
and stored at −22 ◦C in aliquots, while the viral NA (influenza virus strain/California/04/2009;
H1N1; BioTrend, Köln, Germany) in Tris-buffer (20 mM Tris-HCl pH 7.4, 500 mM NaCl, 10% glycine)
was adjusted to 80–120 mU/mL with distilled water and kept in aliquots at −80 ◦C until use. Stock
solutions (0.1–10 mg/mL) of the test substances were prepared in MES-buffer, aqueous ethanol or
DMSO/H2O (1:5 v/v) and serially diluted in MES-buffer for measurements.
To quantify enzyme activity, 60 µL of MES-buffer and 10 µL of diluted VCNA were mixed with
10 µL of varying concentrations of the test substance in black 96-well plates. For analyses of the viral
NA, half of the volumes were used. After agitating gently and incubating for 2 min at 37 ◦C, 20 µL
of the substrate MUNANA (1 mM stock solution) was added, and the fluorescence measured over
the course of 14 min at an excitation wavelength of 360 nm and an emission wavelength of 465 nm.
Appropriate controls were included in the measurements. All assays were at least performed in
triplicates (n = 3–6) and IC50 values for each substance were calculated from fitting curves to data
points (percentage of inhibition vs. concentration) using GraphPad Prism version 6.0 for Windows
(GraphPad Software, La Jolla, CA, USA, www.graphpad.com).
IC50 values are expressed as mean values ± standard deviation for n = 3–6 experiments.
For normally distributed data, first the variance homogeneity test (F-test) was applied, followed
by the t-test. For data with non-normal distributions, the Welch-modified t-test was used. Analysis
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of variance (ANOVA) followed by the Bonferonni’s multiple comparison test was used to evaluate
differences between tests. p-values < 0.05 were considered statistically significant.
4.3. Drug Combination Analysis
The combined effect of zanamivir and EPs® 7630 on VCNA was determined using the diagonal
constant ratio combination method designed by Chou and Talalay [27]. VCNA was incubated with
zanamivir or EPs® 7630 individually and in combination at weight ratios of zanamivir to EPs® 7630
(10:1, 5:1, 1:1, 1:5, and 1:10) as described in Section 4.2. The concentration–efficiency curves of the test
samples were transformed into the double-logarithmic mean action diagram (shape (m), intercepts
and regression coefficients were used to determine the median effect dose Dm).
Dm = 10−(
b
m )
Fraction affected (fa) and fraction unaffected (fu) by the concentration D were calculated by the
median effect equation [27]:
fa
fu
=
(
D
Dm
)m
Dm is the concentration required to produce the median effect.
The CI for quantification of synergism, additive effects, or antagonism was calculated as follows:
CI =
D1
(Dx)1
+
D2
(Dx)2
(exclusivity) (1)
CI =
D1
(Dx)1
+
D2
(Dx)2
+
D1 × D2
(Dx)1 × (Dx)2
(non− exclusivity) (2)
Due to the therapeutic significance of the high degrees of effects, the weighted average CI values
were calculated as
CIwt =
CI50 + 2×CI75 + 3×CI90 + 4×CI95
10
(3)
4.4. Expression and Purification of Recombinant VCNA
The expression vector pET30b(+) that produces Vibrio cholerae serotype O1 (strain ATCC 39315/E1
Tor Inaba N165961) NA was a gift from Prof. G. Taylor, University of St. Andrews, Scotland. VCNA
was produced according to a previously reported method with the following modifications [51].
VCNA was expressed in E. coli Rosetta™ 2 (DE3) (Merck KGaA, Darmstadt, Germany) using an LEX
ultra-high-throughput bench-top bioreactor (Epiphyte3 Inc., Toronto, ON, Canada). Cells were grown
at 37 ◦C in Terrific Broth medium to an optical density at 600 nm (OD600) of about 2.0–2.5, cooled to
17 ◦C, and induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cultures were then
left shaking overnight, and cells were collected by centrifugation.
For purification, cells were resuspended in 20 mM Tris–HCl pH 7.6 supplemented with cOmplete™
ethylenediamine tetra-acetic acid (EDTA)-free protease inhibitor cocktail (Merck KGaA, Darmstadt,
Germany), and lysed by sonication (SONOPULS HD 2200, Bandelin Electronic GmbH & Co. KG,
Berlin, Germany). The purification procedure comprised initial ammonium sulfate precipitation (50%
w/v), desalting on a 26/10 HiPrep Desalting column (GE Healthcare, Munich, Germany) equilibrated
with 10 mM Tris-HCl pH 7.6 and 150 mM NaCl, a Source 30Q anion exchange column, and a final
size-exclusion chromatography on a Superdex 200 prep grade column (XK 26 × 60, GE Healthcare,
Munich, Germany). Purified protein was concentrated to about 6 mg/mL in a buffer containing 20 mM
Tris-HCl, pH 7.6, 0.15 M NaCl, and 10 mM CaCl2.
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4.5. VCNA Crystallization and Structure Determination
The VCNA-inhibitor complexes were crystallized using the sitting-drop vapor-diffusion method
at 20 ◦C by mixing equal volumes (200 nL) of purified protein (see Section 4.4) and reservoir solution,
with a reservoir volume of 75 µL in 96-well plates. VCNA (in 20 mM Tris-HCl pH 7.6, 0.15 M NaCl,
10 mM CaCl2) was complexed with a 20 mM inhibitor (oseltamivir, zanamivir) and concentrated
to 6–7 mg/mL. The VCNA–oseltamivir complex was crystallized using 20% (w/v) polyethylene
glycol (PEG) 3350 and 0.2 M lithium acetate as reservoir solution. For the VCNA–zanamivir complex,
the reservoir solution contained 20% (w/v) PEG 3350 and 0.2 M sodium fluoride. Before flash-freezing
in liquid nitrogen, the crystals were transferred into a cryoprotectant consisting of reservoir solution
supplemented with 30% (v/v) glycerol.
X-ray diffraction data were collected at beamline BL14.1 at the Helmholtz-Zentrum Berlin [52]
at a wavelength of 0.9184 Å and a temperature of 100 K. Data were processed with the program
XDSAPP [53]. The structure was solved by molecular replacement using the program PHASER [54]
and uncomplexed VCNA as search model (PDB entry 1KIT) [34]. Structure refinement was done
with the PHENIX program suite [55]. The graphics program COOT was used for manual model
building and visualization [56]. PRODRG was used for generation of ligand restraint parameters [57].
Data collection and refinement statistics are reported in Table 5. Coordinates and structure factors for
the VCNA-inhibitor complex structures have been deposited in the Protein Data Bank under accession
codes 6EKS and 6EKU.
4.6. Multiple Sequence Alignment
The structure-based sequence alignment was performed with PDBeFold [58] using the PDB
entries 1W0O (VCNA) and 3NSS (H1N1-NA). The aligned amino-acid sequences were transferred
to the Clustal Omega server [59] to generate the input file for TEXshade [60], which was used for
final visualization. The Uniprot accession numbers for Vibrio cholerae NA and influenza virus H1N1
A/California/04/2009 NA are P0C6E9 and C3W5S3.
Supplementary Materials: Supplementary Materials are available online.
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